hotspot -WSS

hotspot

author：focus 2025-09-30 20:46:45 - browse：2376

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

hotspot

WSS

How the Dana

Covid vaccine financial winners and losers, from Pfizer to Novavax

Ionis has late

Kaiser Permanente unions announce official strike date

FDA seeks to regulate lab

Merck drug for rare lung condition set for approval in U.S.

focus

hotspot

focus

How to save PrEP access — and even expand it

Vertex Pharmaceuticals may move headquarters in Boston

Medical records are filled with copy

Readout Newsletter: Merck, Vertex, and Viking updates

Trump demands the U.S. pay no more for drugs than other countries … again

WHO recommends dropping component of many flu vaccines

ChatGPT in medicine: STAT answers readers' burning questions

Decaf coffee targeted by food safety group under obscure FDA rule

How to save PrEP access — and even expand it

FDA advisers vote against ALS treatment from BrainStorm

hotspot

Abortion pill case raises question: who can sue the FDA?

Why do women spend more than men on medical expenses?

FDA seeks to regulate lab

Menendez indictment could see pharma lose a key ally

FDA's naming rule on biosimilars has undermined competition

Inequities make cancer less preventable for women: report

knowledge

hotspot

Wikipedia

focus